Latest Breaking News On - Phill huillier - Page 1 : comparemela.com

CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists

CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesAndrea necchiRoys herbstPhil lhuillierRoy herbstPetros grivasRoy baynesCornell university medical collegeUniversity of milanNational cancer institute thoracic malignancy steering committeeUniversity of washingtonTranslational researchUniversity of witwatersrandResearch foundationUniversity of texas md anderson cancer centerMerck research laboratories

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ignacio meleroPhil lhuillierCatalym gmbOncology congressDepartment of immunologyInternational coordinating investigator profEuropean society for medical oncologyTrophic communicationsObjective response ratesTed human effector cell relocation phaseEuropean societyMedical oncologyImmuno oncology congressGrowth differentiationInternational coordinating investigatorUniversidad de navarra

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesPhil lhuillierChristine schuberth wagnerCatalym gmbTrophic communicationsSociety for immunotherapy of cancerChief scientific officerCentral mediatorT cell engagerTed human effector cell relocationGrowth differentiationPhill huillier

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Catalym gmbPhil lhuilierAndrea necchiPhil lhuillierTrophic communicationsGenitourinary medical oncologyRaffaele hospitalPrincipal investigatorPhill huillierChief executive officerTed human effectorRelocation phaseGrowth differentiationPhill huilier

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

Mecklenburg vorpommernUnited statesPhil lhuilierIgnacio melero bermejoPhil lhuillierStefan klotterCatalym gmbInternational coordinating investigator profAmerican society of clinical oncologyTrophic communicationsTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationEugen leo